Fiscal year 2019 may have marked a turnaround for Dr. Reddy's Laboratories Ltd. but the slow traction of some new products in the US and potential delays in launch timelines of certain other key products like generic Copaxone (glatiramer acetate injection) appear to have dulled investor sentiment, at least for now.
Management reported a “much more stable” pricing environment in the US compared with the last few quarters and increased launch momentum since January 2019, including for limited competition products like propofol injection, daptomycin and testosterone gel